Einblicke in Chemietrends und neue Technologien
59 Artikel insgesamt

The reported ene and epoxide modifications are not side-chain-specific handling details; they are described on the fluorene core shared by Fmoc-protected amino acids. That matters because solid-phase peptide synthesis normally treats Fmoc as a temporary protecting group, while the modified cores were reported to behave differently under common deprotection and cleavage conditions.

When a peptide carries two, three, or four disulfide bonds, the question is not whether cysteines can be oxidized — it is whether they pair correctly. Orthogonal protection answers this by assigning each cysteine pair a protecting group removable under conditions that leave the others intact. The most widely used group in Fmoc-SPPS is trityl (Trt), which cleaves with 1–5% TFA and is the default for single-disulfide peptides. But Trt alone cannot support regioselective multi-disulfide assembly.

For a peptide process team, resin selection is a design decision made before the first coupling cycle. The reported selection model starts with the C-terminal functional group needed after cleavage, then checks whether the sequence raises risks such as diketopiperazine formation, racemization, steric hindrance, poor swelling, or a need for protected fragments.

Antimicrobial resistance continues to drive interest in peptide-based antibiotics as an alternative to conventional small molecules. However, optimizing peptide leads for activity, selectivity, and stability can require repeated synthesis, purification, and assay cycles. Each round consumes time and material, limiting how many candidates can be explored experimentally.

Peptide modification chemistry changes the functional groups attached to a peptide or protein scaffold. For R&D and CDMO teams, the practical question is not only which modification appears on a sequence; it is where the modification sits, whether it survives the route, how it changes purification, and which analytical methods can distinguish intended material from close impurities.

The reported 2026 ASCO education-session themes frame next-generation antibody-drug conjugate work around engineering variables: target engagement, payload pairing, payload novelty, DAR design, and dose strategy. For CHEMOS readers, the useful point is not that any format has been proven superior. It is that each new ADC format moves more risk into linker-payload synthesis, conjugation control, analytical methods, formulation assumptions, and evidence discipline.